Join our daily newsletter At The Bell to receive exclusive market insights
- Immutep (IMM) has been granted a new patent for “Combined Preparations for the Treatment of Cancer” by the Chinese Patent Office until 2034
- The new patent protects Immutep’s intellectual property relating to combination chemotherapies commonly used in China and is exclusively licensed to IMM’s respective partner in the country, EOC Pharma
- Broadly, IMM affirms the new patent provides protection for a range of novel and highly relevant chemoimmunotherapies and builds on the ASX-lister’s existing patents across Europe, Australia, Japan and the U.S.
- The patent expires on December 19, 2034
- Immutep shares are trading 5.08 per cent higher following the announcement at 62 cents
Immutep (IMM) has been granted a new patent for “Combined Preparations for the Treatment of Cancer” by the Chinese Patent Office until 2034.
The new patent protects Immutep’s intellectual property relating to combination therapy which includes a lead active immunotherapy candidate named eftilagimod alpha (efti or IMP321) — a LAG-3 fusion protein and chemotherapy agent.
The patent covers the chemotherapy agent oxaliplatin, carboplatin, or topotecan in the territory of mainland China and is exclusively licensed to Immutep’s partner in China, EOC Pharma.
Broadly, IMM affirms the new patent provides protection in China for a range of novel and highly relevant chemoimmunotherapies and builds on the ASX-lister’s existing patents across Europe, Australia, Japan and the U.S.
Dr Frédéric Triebel, Immutep’s Chief Scientific Officer and Chief Medical Officer, commented on the news.
“Oxaliplatin, carboplatin and topotecan continue to be commonly used forms of chemotherapy in China and more broadly,” he explained.
“Furthermore, combinations of chemotherapy and active immunotherapies have begun to be approved for the treatment of advanced solid tumors in recent years.
“As such, this new patent provides protection in the important Chinese territory for a range of novel and highly relevant chemoimmunotherapies,” he concluded.
The patent expires on December 19, 2034.
Immutep shares are trading 5.08 per cent higher following the announcement at 62 cents at 2:38 pm AEST.
